ScreenerHero

TLPH Talphera, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · talphera.com
1.050USD-5.41%Mkt Cap: 54.50M $P/E: —

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized fo…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap54.50M USD
Enterprise Value47.04M USD
Revenue (TTM)1.00K USD
Gross Profit-6.70M USD
Net Income (TTM)-14.29M USD
Revenue/Share0.00 USD
Last Price1.050 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.97
PEG—
EV/EBITDA—
EV/Revenue47038.43
P/S57615.44
P/B3.99
EPS (TTM)-0.25
EPS (Forward)-0.22
52W Range
0.690041% of range1.570
52W High1.570 USD
52W Low0.6900 USD
Profitability
Gross Margin0.00%
Oper. Margin-1474700.00%
EBITDA Margin0.00%
Profit Margin-51035.71%
ROE-83.89%
ROA-48.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.36M USD
CapEx (TTM)—
FCF Margin-687087.50%
FCF Yield-12.61%
Net Debt-10.58M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity45.11
Current Ratio4.29
Quick Ratio4.08
Book Value/Sh0.28 USD
Cash/Share0.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 26, 2022
Analyst Consensus
Rating—
Target (Mean)3.125 USD
Upside (mean)+197.6%
Target Range3.000 USD – 3.500 USD
3.000+197.6% to mean3.500
# Analysts4
Ownership
Shares Out.51.91M
Float25.23M
Insiders21.41%
Institutions46.03%
Short Interest
Short Ratio4.0d
Short % Float1.67%
Short % Out.1.35%
Shares Short700.72K
Short (prev mo.)515.15K
Technical
SMA 501.233 (-14.9%)
SMA 2001.015 (+3.4%)
Beta0.68
S&P 52W Chg16.45%
Avg Vol (30d)171.65K
Avg Vol (10d)182.40K
Technical Indicators
RSI (14)32.1
MACD-0.0350
MACD Signal-0.0266
MACD Hist.-0.0085
BB Upper1.266 USD
BB Middle1.173 USD
BB Lower1.079 USD
BB Width16.00%
ATR (14)0.0528 USD
Vol Ratio (20d)1.86x